Recombinant human bone morphogenetic protein‐7 in maxillary sinus floor elevation surgery in 3 patients compared to autogenous bone grafts

Bergh, J. P. A. van den; Bruggenkate, C.M. ten; Groeneveld, Herman; Burgér, E.H.; Tuinzing, D.B.

doi:10.1034/j.1600-051x.2000.027009627.x

Cited by 118 publications

(91 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BMP2 is known to induce osteogenesis and new bone formation 19,20) . BMP7 is a multifunctional member of the BMP family with multiple effects on bone formation and regeneration [21][22][23] . BMP2 and BMP7 homodimers were reported to accelerate bone formation efficiently.…”

Section: Discussionmentioning

confidence: 99%

BMP2/7 heterodimer is a stronger inducer of bone regeneration in peri-implant bone defects model than BMP2 or BMP7 homodimer

et al. 2012

View full text Add to dashboard Cite

This study aimed to compare the effects of bone morphogenetic protein BMP2/7 heterodimer and BMP homodimers on bone regeneration in bone defects model. Identical peri-implant bone defects model were created using proper controls on the frontal skull in 18 minipigs. Collagen sponges with low-dose (30 ng/mL) BMP2/7 heterodimer, BMP2 or BMP7 homodimer were filled in the defects. New bone formation and the expression of type I collagen (Col1), alkaline phosphatase (ALP) and osteocalcin (OCN) were evaluated after 2, 3, and 6 weeks of implantation. BMP2/7 resulted in significantly higher new bone areas percentage in the defect region than BMP2 and BMP7 (p<0.05). Immunohistochemical staining of Col1, ALP and OCN was stronger in BMP2/7 group than BMP2, BMP7 and control group (p<0.05). These results demonstrate that BMP2/7 heterodimer is a stronger inducer of osteoblastogenesis and could be applied at low dose to reduce the cost and side effects of BMP homodimers.

show abstract

Section: Discussionmentioning

confidence: 99%

BMP2/7 heterodimer is a stronger inducer of bone regeneration in peri-implant bone defects model than BMP2 or BMP7 homodimer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…36,37 A few human trials using BMPs reported to date have utilized superphysiological doses of BMPs that result in "dose-dumping" of potent morphogens in the wound site. 15,38,39 This use of bolus delivery can lead to systemic toxicity, 40 likely through cytokine diffusion into the bloodstream. 41 This approach using ex vivo gene transfer of SDFs provided a more robust response in the stimulation of osteogenesis as compared to our previous efforts using direct gene transfer 42 (and unpublished data).…”

Section: Discussionmentioning

confidence: 99%

Gene Therapy of Bone Morphogenetic Protein for Periodontal Tissue Engineering

Anusaksathien

et al. 2003

Journal of Periodontology

159

150

View full text Add to dashboard Cite

Background-The reconstruction of lost periodontal support including bone, ligament, and cementum is a major goal of therapy. Bone morphogenetic proteins (BMPs) have shown much potential in the regeneration of the periodontium. Limitations of BMP administration to periodontal lesions include need for high-dose bolus delivery, BMP transient biological activity, and low bioavailability of factors at the wound site. Gene transfer offers promise as an alternative treatment strategy to deliver BMPs to periodontal tissues.

show abstract

“…An extensive cementogenesis was considered the most significant effect of BMP-7 in bony defects in baboons [122,123]. Improvement of bone formation around titanium implants was also demonstrated by studies in animals [124,125], although no significant benefit was observed when rhBMP-7 was compared with bone grafts for maxillary bony defects in preclinical [126] and pilot human clinical studies [127].…”

Section: Growth Factor Applications For Oral and Periodontal Tissue Ementioning

confidence: 99%

Growth factor delivery for oral and periodontal tissue engineering

Kaigler

Cirelli

Giannobile

2006

Expert Opinion on Drug Delivery

164

153

View full text Add to dashboard Cite

The treatment of oral and periodontal diseases and associated anomalies accounts for a significant proportion of the healthcare burden, with the manifestations of these conditions being functionally and psychologically debilitating. Growth factors are critical to the development, maturation, maintenance and repair of craniofacial tissues, as they establish an extracellular environment that is conducive to cell and tissue growth. Tissue-engineering principles aim to exploit these properties in the development of biomimetic materials that can provide an appropriate microenvironment for tissue development. These materials have been constructed into devices that can be used as vehicles for delivery of cells, growth factors and DNA. In this review, different mechanisms of drug delivery are addressed in the context of novel approaches to reconstruct and engineer oral-and tooth-supporting structures, namely the periodontium and alveolar bone.

show abstract

Recombinant human bone morphogenetic protein‐7 in maxillary sinus floor elevation surgery in 3 patients compared to autogenous bone grafts

Cited by 118 publications

References 13 publications

BMP2/7 heterodimer is a stronger inducer of bone regeneration in peri-implant bone defects model than BMP2 or BMP7 homodimer

BMP2/7 heterodimer is a stronger inducer of bone regeneration in peri-implant bone defects model than BMP2 or BMP7 homodimer

Gene Therapy of Bone Morphogenetic Protein for Periodontal Tissue Engineering

Growth factor delivery for oral and periodontal tissue engineering

Contact Info

Product

Resources

About